Alistair Reid

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Katayoun Rezvani, Letizia Foroni, K. Rezvani, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Technical aspects and clinical applications of measuring BCR‐ABL1 transcripts number in chronic myeloid leukemia

Letizia Foroni, John Goldman, D. Marin, 2009, American journal of hematology.